Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

Augmented antitumor vaccines were synthesized by conjugating albumin-binding moieties to peptide antigens. This platform improved vaccine stability and lymphatic distribution, leading to augmented and extended antigen presentation in lymph nodes and enhanced CD8+ T-cell priming. Antitumor T-cell responses have the potential to be curative in cancer patients, but the induction of potent T-cell immunity through vaccination remains a largely unmet goal of immunotherapy. We previously reported that the immunogenicity of peptide vaccines could be increased by maximizing delivery to lymph nodes (LNs), where T-cell responses are generated. This was achieved by conjugating the peptide to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-PEG (DSPE-PEG) to promote albumin binding, which resulted in enhanced lymphatic drainage and improved T-cell responses. Here, we expanded upon these findings and mechanistically dissected the properties that contribute to the potency of this amphiphile-vaccine (amph-vaccine). We found that multiple linkage chemistries could be used to link peptides with DSPE-PEG, and further, that multiple albumin-binding moieties conjugated to peptide antigens enhanced LN accumulation and subsequent T-cell priming. In addition to enhancing lymphatic trafficking, DSPE-PEG conjugation increased the stability of peptides in serum. DSPE-PEG peptides trafficked beyond immediate draining LNs to reach distal nodes, with antigen presented for at least a week in vivo, whereas soluble peptide presentation quickly decayed. Responses to amph-vaccines were not altered in mice deficient in the albumin-binding neonatal Fc receptor (FcRn), but required Batf3-dependent dendritic cells (DCs). Amph-peptides were processed by human DCs equivalently to unmodified peptides. These data define design criteria for enhancing the immunogenicity of molecular vaccines to guide the design of next-generation peptide vaccines. Cancer Immunol Res; 6(9); 1025–38. ©2018 AACR.

[1]  J. Petrik,et al.  Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections , 2017, Scientific Reports.

[2]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[3]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[4]  Klavs F Jensen,et al.  A fully automated flow-based approach for accelerated peptide synthesis. , 2017, Nature chemical biology.

[5]  Gajendra P. S. Raghava,et al.  PEPlife: A Repository of the Half-life of Peptides , 2016, Scientific Reports.

[6]  S. Le Gall,et al.  Variable Processing and Cross-presentation of HIV by Dendritic Cells and Macrophages Shapes CTL Immunodominance and Immune Escape , 2015, PLoS pathogens.

[7]  S. Rosenberg.  Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment , 2014, Nature Reviews Clinical Oncology.

[8]  D. Richardson,et al.  Unraveling the mysteries of serum albumin—more than just a serum protein , 2014, Front. Physiol..

[9]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[10]  P. Ascenzi,et al.  α-Tocopherol binding to human serum albumin. , 2013, BioFactors.

[11]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[12]  Maarten Danial,et al.  Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation. , 2012, Bioconjugate chemistry.

[13]  E. Fiebiger,et al.  Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8−CD11b+ dendritic cells , 2011, Proceedings of the National Academy of Sciences.

[14]  Hans J. Vogel,et al.  Serum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs , 2010, PloS one.

[15]  S. H. van der Burg,et al.  Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.

[16]  R. Offringa,et al.  Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. , 2009, Cancer research.

[17]  C. Liu,et al.  IFN-α Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity1 , 2009, The Journal of Immunology.

[18]  P. Klenerman,et al.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance , 2009, Nature Immunology.

[19]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[20]  J. Andersen,et al.  Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.

[21]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[22]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[23]  R. Offringa,et al.  Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation , 2008, European journal of immunology.

[24]  L. Pease,et al.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. , 2007, Cancer research.

[25]  C. Holmes,et al.  Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. , 2006, Experimental hematology.

[26]  K. Schwarz,et al.  Long‐lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation , 2006, European journal of immunology.

[27]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[28]  R. Kennedy,et al.  Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. , 2003, Cancer research.

[29]  C. Tsopelas,et al.  Why certain dyes are useful for localizing the sentinel lymph node. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[31]  A. Thomson,et al.  Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. , 2002, Blood.

[32]  S. Ascarateil,et al.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines , 2002, Expert review of vaccines.

[33]  B. Walker,et al.  HLA-B57-Restricted Cytotoxic T-Lymphocyte Activity in a Single Infected Subject toward Two Optimal Epitopes, One of Which Is Entirely Contained within the Other , 2000, Journal of Virology.

[34]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[35]  R. Offringa,et al.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Pircher,et al.  T cell priming versus T cell tolerance induced by synthetic peptides , 1995, The Journal of experimental medicine.

[37]  V. Lindner,et al.  Binding properties of circulating Evans blue in rabbits as determined by disc electrophoresis. , 1982, Atherosclerosis.

[38]  H. L. Poulsen.  Interstitial fluid concentrations of albumin and immunoglobulin G in normal men. , 1974, Scandinavian journal of clinical and laboratory investigation.